Navigation Links
Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
Date:5/4/2009

ATLANTA, May 4 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien(TM) (fluocinolone acetonide (FA) intravitreal insert) will be presented today at 2:00 p.m. at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Ft. Lauderdale, FL.

The data in the presentation, entitled "Pharmacokinetics and Pharmacodynamics of Iluvien(TM) (FA intravitreal insert) for DME," were derived from the FAMOUS Study Group, which in addition to measuring systemic levels of FA, also assessed anterior chamber levels of FA, and assessed correlations between these levels and clinical outcomes.

A total of 37 subjects with DME were randomized, 20 patients on the low dose of Iluvien and 17 patients on the high dose of Iluvien. Results showed an improvement in best corrected visual acuity associated with a reduction in center subfield thickness in a substantial number of patients for both doses, as well as no evidence of elevated intraocular pressure in the low dose.

"Alimera is excited to share more details of this study," said Dan Myers, CEO, Alimera Sciences. "We believe these results continue to be in line with our expectations regarding the safety and efficacy of Iluvien."

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.


'/>"/>
SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
2. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
5. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):